Mylan-Biocon’s breast cancer biosimilar receives ANVISA approval
Biocon and Mylan’s proposed trastuzumab has received approval from Brazilian regulatory agency ANVISA, through their partner Libbs Farmaceutica (Libbs). The approved product is co-developed by Biocon...